Imricor enters into license agreement with Sorin Group to develop MRI compatible technology

Focused on Developing MRI Conditional Leads for Cardiac Rhythm Management Products

Imricor Medical Systems, Inc. today announced that it has entered into a license agreement with Sorin Group to develop magnetic resonance imaging (MRI) compatible leads for use with Sorin implantable cardiac rhythm management devices.

"Imricor has unique knowledge and extensive expertise in the field of MRI compatible technology for implanted medical devices. By means of this agreement, we are working together to develop cardiac rhythm management products that can be used in MRI environments," said Stefano Di Lullo, President, Cardiac Rhythm Management Business Unit, Sorin Group.

"We realize that many patients will benefit from the availability of MR Conditional implanted devices, and Imricor's novel intellectual property can be applied to many of these devices. We look forward to working with Sorin Group to design MR Conditional solutions for their cardiac rhythm management products that outperform anything currently on the market," said Steve Wedan, Imricor's President and Chief Executive Officer.